A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC)

Summary

This is a prospective, randomized, multi-center, active-controlled, double-blind, double-dummy, multicenter, non-inferiority study comparing the clinical efficacy, safety and tolerability of ProF-001 to fluconazole.

Timeline

Start

2019-10-01

Primary completion

2022-11-01

Completion

2022-12-30

Publications

• Abdelkader SI, Aboelenin SA, Abdelhafez RA, Nabhan AF. Oral versus topical maintenance antifungal therapy for recurrent vulvovaginal candidiasis: a systematic review and meta-analysis. BMC Womens Health. 2026 Mar 18;26(1):196. doi: 10.1186/s12905-026-04356-8.

Drugs

Indications